生長狀態(tài):懸浮生長
細(xì)胞形態(tài):淋巴樣
免疫類型:IgG
運(yùn)輸方式:凍存運(yùn)輸
是否是腫瘤細(xì)胞:0
物種來源:小鼠
數(shù)量:大量
ATCC Number:HB-8672?
規(guī)格:0.2ml Designations: WI-MN-1
Depositors: ?Wadley Technologies, Inc.
Isotype: IgG
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human melanoma associated antigens
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with the G-361 human human melanoma cell line see ATCC CRL-1424 ).
Spleen cells were fused with P3/NS1/1-Ag4-1 myeloma cells.
The antibody reacts with antigens associated with human melanoma cells.
The antibody precipitates antigens of 108000 and 38000 daltons from G-361 lysates.
It reacts with human melanoma cell lines and with WISH (human amnion cell line with HeLa markers) and Rc2a (human acute myelomonocytic leukemia cell line).
It did not react with other line tested or with surgical specimens of non-melanoma neoplasms or with normal tissue.
Most surgical specimens of melanoma were stained positively with WI-MN-1.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine, 1 mM sodium pyruvate, 3.88 mg/L thymidine, 13.61 mg/L hypoxanthine, and 0.05 mg/ml gentamicin, 90%; heat-inactivated horse serum, 10%
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: RPMI 1640 medium, 70%, heat-inactivated horse serum, 20%; DMSO, 10%
References: 21932: Khan A. Monoclonal antibodies to novel melanoma-associated antigens. US Patent 4,851,510 dated Jul 25 1989